Tuesday August 20, 9:03 am Eastern Time

Press Release

SOURCE: ProteoTech Inc.

ProteoTech Receives $1.2 Million SBIR Award From the National Institute of Aging

KIRKLAND, Wash., Aug. 20 /PRNewswire/ -- ProteoTech Inc. today announced that it has received a Phase II Small Business Innovative Research (SBIR) award from the National Institute on Aging. The $1.2 million award to ProteoTech (with principal investigator, Gerardo Castillo, Ph.D.) will fund a 2.5 year drug development program for peptide inhibitors for the treatment of Alzheimer's disease. This is the 3rd Phase II SBIR award received by ProteoTech from the National Institute on Aging for its different drug development programs related to the treatment of Alzheimer's disease and related disorders.

- (Photo: http://www.newscom.com/cgi-bin/prnh/20020220/SFW009LOGO)

In related news, ProteoTech scientists recently made three presentations at the 8th International Meeting on Alzheimer's Disease and Related Disorders, in Stockholm, Sweden. Alan D. Snow, Ph.D., President & CSO of ProteoTech, gave an oral presentation relating to ProteoTech's plant-derived therapeutics for the treatment of Alzheimer's disease. In transgenic mouse models of Alzheimer's disease, Dr. Snow presented data demonstrating that PTI-777 treatment causes a marked reduction and clearance of pre-formed amyloid plaques and cerebrovascular deposits in the brains of old transgenic animals that develop many of the neuropathological hallmarks observed in human Alzheimer's disease. In another study, Gerardo Castillo, Ph.D., presented data demonstrating that PTI-777 has the ability to cross the blood-brain barrier and enter the brain parenchyma when administered peripherally, an important attribute for the development of a future Alzheimer's drug. Lastly, Joel Cummings presented data pertaining to the presence and accumulation of heparan sulfate proteoglycans in the amyloid plaques and cerebrovascular amyloid deposits in the brains of APP transgenic mice. These latter studies suggest that specific proteoglycans play a role in amyloid formation and deposition as observed in both transgenic mouse and in human cases of Alzheimer's disease.

ProteoTech is a private, product oriented Company that utilizes Proteoglycan Technologies to discover and develop drugs for treating human diseases, including Alzheimer's disease, Parkinson's disease, prion diseases,type 2 diabetes and systemic amyloidosis. For further information pertaining to licensing opportunities regarding ProteoTech's Alzheimer's program pleasecontact Alan D. Snow, Ph.D., President & CSO at snow@proteotech.com.

SOURCE: ProteoTech Inc.

Email this story - Most-emailed articles - Most-viewed articles

Related News Categories: health care, medical/pharmaceutical